Drugs / 64Cu-DOTA-TLX592
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04726033 | Aug 2021 → Dec 2023 | metastatic prostate carcinoma | Telix Pharmaceuticals (Innovations) Pty Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-DOTA-TLX592 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04726033 ↗ |
| Modality | Monoclonal antibody | “humanised, engineered monoclonal antibody” NCT04726033 ↗ |
| Route | Intravenous | “intravenously administered” NCT04726033 ↗ |